Mga Batayang Estadistika
| CIK | 1424812 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Amarantus BioScience Holdings, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| April 18, 2022 |
Term Sheet for Acquisition of Assets in exchange for Settlement of Debt Exhibit 99.1 Term Sheet for Acquisition of Assets in exchange for Settlement of Debt This term sheet (the ?Term Sheet?) summarizes the principal terms with respect to a potential transaction between Amarantus BioScience Holdings, Inc. (together with its affiliates, ?Amarantus?) and TE Debt Holders (as defined by certain debt holders having entered into a Tender Exchange of Securities in March 2018 |
|
| April 18, 2022 |
AMBS / Amarantus Bioscience Holdings Inc / Dominion Capital L.L.C. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) AMARANTUS BIOSCIENCE HOLDINGS, INC. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 02300U205 (CUSIP Number) Mikhail Gurevich Dominion Capital LLC 256 W. 38th Street, 15th Floor New York, NY 10018 (203) 293-8313 With a copy |
|
| April 18, 2022 |
AMBS / Amarantus Bioscience Holdings Inc / Anson Funds Management LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) AMARANTUS BIOSCIENCE HOLDINGS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 02300U205 (CUSIP Number) Bruce R. Winson Anson Funds Management LP 16000 Dallas Parkway Suite 800 Dallas, TX 75248 (214) 866-0202 With a cop |
|
| April 18, 2022 |
AMBS / Amarantus Bioscience Holdings Inc / Lorient Ventures Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) AMARANTUS BIOSCIENCE HOLDINGS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 02300U205 (CUSIP Number) Eliyahu Hassett Lorient Ventures Limited Palm Grove House, P.O. Box 438 Road Town, Tortola, British Virgin Islands |
|
| April 18, 2022 |
Term Sheet for Acquisition of Assets in exchange for Settlement of Debt Exhibit 99.1 Term Sheet for Acquisition of Assets in exchange for Settlement of Debt This term sheet (the ?Term Sheet?) summarizes the principal terms with respect to a potential transaction between Amarantus BioScience Holdings, Inc. (together with its affiliates, ?Amarantus?) and TE Debt Holders (as defined by certain debt holders having entered into a Tender Exchange of Securities in March 2018 |
|
| April 18, 2022 |
Term Sheet for Acquisition of Assets in exchange for Settlement of Debt Exhibit 99.1 Term Sheet for Acquisition of Assets in exchange for Settlement of Debt This term sheet (the ?Term Sheet?) summarizes the principal terms with respect to a potential transaction between Amarantus BioScience Holdings, Inc. (together with its affiliates, ?Amarantus?) and TE Debt Holders (as defined by certain debt holders having entered into a Tender Exchange of Securities in March 2018 |
|
| October 9, 2020 |
AMBS / Amarantus Bioscience Holdings, Inc. / Lorient Ventures Ltd - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) AMARANTUS BIOSCIENCE HOLDINGS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 02300U205 (CUSIP Number) Eliyahu Hassett Lorient Ventures Limited Palm Grove House, P.O. Box 438 Road Town, Tortola, British Virgin Islands + |
|
| October 9, 2020 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the common stock, par value $0.001 per share, of Amarantus Biosciences Holdings, Inc., a Nevada corporation, and furth |
|
| October 9, 2020 |
Exhibit 99.1 AGREEMENT THIS AGREEMENT, dated as of October 2, 2020, (the “Agreement”) is by and between Dominion Capital LLC (“Dominion”), Anson Investments Master Fund LP (“AIMF”) and Lorient Ventures Ltd. WHEREAS, the parties believe that the value of their investment in the securities listed on Schedule I to this Agreement (“Securities”), of Amarantus Biosciences Holding Inc. (the “Company”), h |
|
| October 5, 2020 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the common stock, par value $0.001 per share, of Amarantus Biosciences Holdings, Inc., a Nevada corporation, and furth |
|
| October 5, 2020 |
AMBS / Amarantus Bioscience Holdings, Inc. / Anson Funds Management LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) AMARANTUS BIOSCIENCE HOLDINGS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 02300U205 (CUSIP Number) Bruce R. Winson Anson Funds Management LP 5950 Berkshire Lane, Suite 210 Dallas, TX 75225 (214) 866-0202 With a copy |
|
| October 5, 2020 |
Exhibit 99.1 AGREEMENT THIS AGREEMENT, dated as of October 2, 2020, (the “Agreement”) is by and between Dominion Capital LLC (“Dominion”), Anson Investments Master Fund LP (“AIMF”) and Lorient Ventures Ltd. WHEREAS, the parties believe that the value of their investment in the securities listed on Schedule I to this Agreement (“Securities”), of Amarantus Biosciences Holding Inc. (the “Company”), h |
|
| October 5, 2020 |
Exhibit 99.1 AGREEMENT THIS AGREEMENT, dated as of October 2, 2020, (the “Agreement”) is by and between Dominion Capital LLC (“Dominion”), Anson Investments Master Fund LP (“AIMF”) and Lorient Ventures Ltd. WHEREAS, the parties believe that the value of their investment in the securities listed on Schedule I to this Agreement (“Securities”), of Amarantus Biosciences Holding Inc. (the “Company”), h |
|
| October 5, 2020 |
AMBS / Amarantus Bioscience Holdings, Inc. / Dominion Capital L.L.C. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) AMARANTUS BIOSCIENCE HOLDINGS, INC. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 02300U205 (CUSIP Number) Mikhail Gurevich Dominion Capital LLC 256 W. 38th Street, 15th Floor New York, NY 10018 (203) 293-8313 With a copy t |
|
| October 5, 2020 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the common stock, par value $0.001 per share, of Amarantus Biosciences Holdings, Inc., a Nevada corporation, and furth |
|
| January 10, 2020 |
AMARANTUS BIOSCIENCE HOLDINGS, INC. January 9, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Amarantus Bioscience Holdings, Inc. Request for Withdrawal of Offering Statement on Form 1-A Submitted January 9, 2020 File No. 024-11138 Ladies and Gentlemen: Amarantus Bioscience Holdings, Inc. (Applicant), hereby appl |
|
| January 9, 2020 |
Opinion of Eilers Law Group, P.A. regarding legality of the securities covered in this Offering* Exhibit 12.1 1000 Fifth Street PO Box 5025 Suite 200 – P2 Asheville, NC 28813 Miami Beach, FL 33139 Phone: 786.273.9152 www.eilerslawgroup.com January 9, 2020 Gentlemen: We are acting as counsel to Amarantus Bioscience Holdings, Inc. (the “Company”) in connection with the preparation and filing with the Securities and Exchange Commission, under the Securities Act of 1933, as amended, of the Compan |
|
| January 9, 2020 |
AMBS / Amarantus Bioscience Holdings, Inc. PART II AND III - - PRELIMINARY OFFERING CIRCULAR An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. |
|
| January 9, 2020 |
Opinion of Eilers Law Group, P.A. regarding legality of the securities covered in this Offering* Exhibit 12.1 1000 Fifth Street PO Box 5025 Suite 200 – P2 Asheville, NC 28813 Miami Beach, FL 33139 Phone: 786.273.9152 www.eilerslawgroup.com January 9, 2020 Gentlemen: We are acting as counsel to Amarantus Bioscience Holdings, Inc. (the “Company”) in connection with the preparation and filing with the Securities and Exchange Commission, under the Securities Act of 1933, as amended, of the Compan |
|
| January 9, 2020 |
AMBS / Amarantus Bioscience Holdings, Inc. PART II AND III - - PRELIMINARY OFFERING CIRCULAR An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. |
|
| September 27, 2019 |
Eltoprazine 3rd party valuation in Parkinson’s LID Exhibit 6.1 |
|
| September 27, 2019 |
Certificate of Designation Series B Exhibit 2.6 AMARANTUS BIOSCIENCE HOLDINGS, INC. AMENDED AND RESTATED CERTIFICATE OF DESIGNATION, PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE PREFERRED STOCK (PURSUANT TO NRS 78.1955) The undersigned, Gerald F. Commissiong, does hereby certify that: 1. He is the President and Chief Executive Officer of Amarantus BioScience Holding, Inc., a Nevada corporation (the “Corporation”). 2. |
|
| September 27, 2019 |
Certificate of Designation Series C Exhibit 2.7 CERTIFICATE OF DESIGNATION, PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK OF AMARANTUS BIOSCIENCE HOLDINGS, INC. Amarantus BioScience Holdings, Inc., a corporation organized and existing under the laws of the State of Nevada (the “Corporation”), hereby certifies that the Board of Directors of the Corporation (the “Board of Directors”), pursuant to authorit |
|
| September 27, 2019 |
Certificate of Designation Series E EX1A-2A CHARTER 7 f1a2019ex2-9amarantus.htm CERTIFICATE OF DESIGNATION SERIES E Exhibit 2.9 AMARANTUS BIOSCIENCE HOLDINGS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E 12% CONVERTIBLE PREFERRED STOCK (PURSUANT TO NRS 78.1955) The undersigned, Gerald E. Commissiong and Marc E. Faerber, do hereby certify that: 1. They are the Chief Executive Officer and Secretar |
|
| September 27, 2019 |
ESS 3rd party valuation in Parkinson’s LID EX1A-6 MAT CTRCT 9 f1a2019ex6-2amarantus.htm ESS 3RD PARTY VALUATION IN PARKINSON'S LID Exhibit 6.2 |
|
| September 27, 2019 |
Certificate of Designation Series D Exhibit 2.8 AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF AMARANTUS BIOSCIENCE HOLDINGS, INC. Pursuant to Section 78.1955 of the Nevada Revised Statutes SERIES D CONVERTIBLE PREFERRED STOCK On behalf of Amarantus BioScience Holdings, Inc., a Nevada corporation (the “Corporation”), the undersigned hereby certifies that the following resolution has been duly adopted by the board of directors of |
|
| September 27, 2019 |
Certificate of Designation Series A Exhibit 2.5 AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF AMARANTUS BIOSCIENCE HOLDINGS, INC. Pursuant to Section 78.1955 of the Nevada Revised Statutes SERIES A CONVERTIBLE PREFERRED STOCK On behalf of Amarantus BioScience Holdings, Inc., a Nevada corporation (the “Corporation”), the undersigned hereby certifies that the following resolution has been duly adopted by the board of directors of |
|
| September 27, 2019 |
An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. |
|
| November 27, 2018 |
AMBS / Amarantus Bioscience Holdings, Inc. PART II AND III - - An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. |
|
| December 4, 2017 |
AMBS / Amarantus Bioscience Holdings, Inc. FORM 15 OMB APPROVAL OMB Number: 3235-0167 UNITED STATES Expires: March 31, 2018 SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 9, 2017 |
8-K 1 f8k050317amarantusbio.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2017 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (Stat |
|
| April 17, 2017 |
SECOND AMENDMENT TO INTERCREDITOR AND SUBORDINATION GREEMENT Exhibit 10.3 SECOND AMENDMENT TO INTERCREDITOR AND SUBORDINATION GREEMENT This SECOND AMENDMENT TO INTERCREDITOR AND SUBORDINATION AGREEMENT (?Second Amendment?), dated as of April 6, 2017, by and among the holders of the Company?s Series E Preferred Stock (the ?Series E Holders?) and the holders of the Company?s Series H Preferred Stock (?Series H Holders?), Amarantus Bioscience Holdings, Inc. (t |
|
| April 17, 2017 |
SENIOR SECURED CONVERTIBLE NOTE Exhibit 10.4 SENIOR SECURED CONVERTIBLE NOTE NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFEC |
|
| April 17, 2017 |
AMENDMENT NO. 1 TO PLEDGE AGREEMENT Exhibit 10.2 AMENDMENT NO. 1 TO PLEDGE AGREEMENT THIS AMENDMENT NO. 1 ( this ?Amendment?), dated April 6, 2017, to the PLEDGE AGREEMENT, dated as of October 25, 2016 (the ?Agreement?) between Amarantus Biosciences Holdings, Inc. (?Borrower?) and Xpress Group International Limited (?Xpress?) and Dominick Membership, LLC (?Dominick? and together with Xpress, ?Purchasers? and each, a ?Purchaser?) for |
|
| April 17, 2017 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of April 6, 2017, is by and among Amarantus Bioscience Holdings, Inc., a Nevada corporation with offices located at 655 Montgomery Street, Suite 900, San Francisco, CA 9411 (the ?Company?), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a ?Buyer? and |
|
| April 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2017 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or o |
|
| March 28, 2017 |
(Signatures on following page) Exhibit 10.1 CONFIDENTIAL January 3, 2017 Re: Letter of Intent for Tender Exchange of Existing Debt and Equity Securities Prepared for: Dear : This letter agreement, including that certain Addendum of even date thereto include as attached on Exhibit B, sets forth our agreement and understanding as to the essential terms of the tender exchange of existing debt and equity securities of Amarantus Bio |
|
| March 28, 2017 |
(Signatures on following page) Exhibit 10.2 CONFIDENTIAL Re: Letter of Intent for Tender Exchange of Existing Equity Securities Prepared for: Dear : This letter agreement sets forth our agreement and understanding as to the essential terms of the tender exchange of certain existing equity securities of Amarantus BioScience Holdings, Inc. (the "Company") located at 315 Montgomery Street, Suite 900, San Francisco, CA 94104, inclu |
|
| March 28, 2017 |
Exhibit 99.1 Amarantus Enters into a Letter of Intent to Acquire Certain Biotechnology Assets from SeD BioMedical Inc. SINGAPORE and SAN FRANCISCO, February 27, 2017 /PRNewswire/ - ? Amarantus evaluating four SeD BioMedical assets for potential acquisition into its portfolio of biotechnology assets ? LOI contemplates capital infusion into Amarantus to assist in restructuring and long term growth p |
|
| March 28, 2017 |
Exhibit 10.4 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 3, 2017, between Amarantus Bioscience Holdings, Inc., a Nevada corporation (the ?Company?), and the purchaser identified on the signature page hereto (including its successors and assigns, the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement an |
|
| March 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2017 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation |
|
| March 28, 2017 |
Certificate of Designation Series F Exhibit 3.1 AMARANTUS BIOSCIENCE HOLDINGS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES F 8% CONVERTIBLE PREFERRED STOCK (PURSUANT TO NRS 78.1955) The undersigned, Gerald E. Commissiong and Marc E. Faerber, do hereby certify that: 1. They are the President and Secretary, respectively, of Amarantus BioScience Holdings, Inc., a Nevada corporation (the “Corporation |
|
| March 28, 2017 |
Exhibit 3.3 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATION OF AMARANTUS BIOSCIENCE HOLDINGS, Inc. Pursuant to Section 78.1955 of the Nevada Revised Statutes SERIES H CONVERTIBLE PREFERRED STOCK On behalf of Amarantus BioScience Holdings, Inc., a Nevada corporation (the ?Corporation?), the undersigned hereby certifies that the following resolution has been duly adopted by the board of direc |
|
| March 28, 2017 |
(Signatures on following page) Exhibit 10.3 CONFIDENTIAL Re: Letter of Intent for Tender Exchange of Existing Equity Securities Prepared for: Dear : This letter agreement sets forth our agreement and understanding as to the essential terms of the tender exchange of certain existing equity securities of Amarantus BioScience Holdings, Inc. (the "Company") located at 315 Montgomery Street, Suite 900, San Francisco, CA 94104, inclu |
|
| March 28, 2017 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATION OF AMARANTUS BIOSCIENCE HOLDINGS, Inc. Pursuant to Section 78.1955 of the Nevada Revised Statutes SERIES E CONVERTIBLE PREFERRED STOCK On behalf of Amarantus BioScience Holdings, Inc., a Nevada corporation (the ?Corporation?), the undersigned hereby certifies that the following resolution has been duly adopted by the board of direc |
|
| November 8, 2016 |
Exhibit 10.5 CONVERTIBLE PROMISSORY NOTE US $500,000 October 18th, 2016 For good and valuable consideration, Amarantus BioScience Holdings, Inc., a Nevada corporation, (?Maker?), hereby makes and delivers this Convertible Promissory Note (this ?Note?) in favor of BMI Capital Partners International Ltd, (?Holder?), and hereby agree as follows: 1. Principal Obligation and Interest. For value receive |
|
| November 8, 2016 |
Exhibit 10.2 PLEDGE AGREEMENT THIS PLEDGE AGREEMENT (?Agreement?), dated as of October , 2016 between Amarantus Biosciences Holdings, Inc. ("Borrower") by and among (a) Xpress Group International Limited (?Xpress?), Dominick Membership, LLC ("Dominick") and together with Xpress, "Purchasers" and each, a "Purchaser") for the benefit of Purchasers referred to below (it being understood that subject |
|
| November 8, 2016 |
First Amendment to Intercreditor and Subordination Agreement Exhibit 10.3 First Amendment to Intercreditor and Subordination Agreement This FIRST AMENDMENT TO INTERCREDITOR AND SUBORDINATION AGREEMENT (?First Amendment?), dated as of October [], 2016, by and among the holders of the Company?s Series E Preferred Stock (the ?Series E Holders?) and the holders of the Company?s Series H Preferred Stock (?Series H Holders?), Amarantus Bioscience Holdings, Inc. ( |
|
| November 8, 2016 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of October , 2016, is by and among Amarantus Bioscience Holdings, Inc., a Nevada corporation with offices located at 655 Montgomery Street, Suite 900, San Francisco, CA 9411 (the ?Company?), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a ?Buyer? and |
|
| November 8, 2016 |
Amarantus Bioscience Holdings, Inc. Senior Secured Convertible Note Exhibit 10.4 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| November 8, 2016 |
Amarantus Bioscience Holdings CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2016 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation o |
|
| November 8, 2016 |
Exhibit 10.6 CONVERTIBLE PROMISSORY NOTE US $500,000 October 18th, 2016 For good and valuable consideration, Amarantus BioScience Holdings, Inc., a Navadacorporation, (?Maker?), hereby makes and delivers this Convertible Promissory Note (this ?Note?) in favor of Dominick & Dickerman, LLC, (?Holder?), and hereby agree as follows: 1. Principal Obligation and Interest. For value received, Maker promi |
|
| October 27, 2016 |
8-K 1 f8k102616amarantusbio.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2016 Amarantus Bioscience Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (S |
|
| October 7, 2016 |
Amarantus Bioscience Holdings AMENDMENT NO. 2 TO PRELIMINARY PROXY STATEMENT PRER14A 1 prer14a0916a2amarantusbio.htm AMENDMENT NO. 2 TO PRELIMINARY PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for the use of the Commission only (as permit |
|
| October 6, 2016 |
Termination of a Material Definitive Agreement, Other Events 8-K 1 f8k093016amarantus.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2016 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 ( |
|
| September 9, 2016 |
Amarantus Bioscience Holdings AMENDMENT NO. 1 TO PRELIMINARY PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 15, 2016 |
Amarantus Bioscience Holdings NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2016 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Fo |
|
| August 15, 2016 |
Amarantus Bioscience Holdings NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2016 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Fo |
|
| August 8, 2016 |
8-K 1 f8k080716amarantus.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2016 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (Stat |
|
| August 5, 2016 |
Amarantus Bioscience Holdings PRELIMINARY PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| July 8, 2016 |
8-K 1 f8k070116amarantus.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2016 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State |
|
| July 1, 2016 |
8-K 1 f8k062716amarantusbio.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2016 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (St |
|
| June 1, 2016 |
Amarantus Bioscience Holdings QUARTERLY REPORT (Quarterly Report) 10-Q 1 f10q0316amarantusbio.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: MARCH 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commiss |
|
| May 16, 2016 |
Amarantus Bioscience Holdings NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on F |
|
| May 16, 2016 |
Amarantus Bioscience Holdings ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to 000-55016 (Commission file number) Amarantus Bioscience Holdings, Inc. (Exact name |
|
| May 16, 2016 |
EXHIBIT 21.1 Subsidiaries Amarantus Therapeutics, Inc., a Nevada corporation Amarantus Therapeutics, Inc., a Delaware corporation Amarantus MA, Inc., a Massachusetts corporation Amarantus Diagnostics Inc., a Delaware corporation |
|
| April 21, 2016 |
Exhibit 10.4 EXECUTION VERSION SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of April 14, 2016 (this “Agreement”), is among Amarantus Bioscience Holdings, Inc., a Nevada corporation (the “Company”), all of the Subsidiaries of the Company (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”) and the holders of the Company’s 12% Original Issue Discount Senior Secu |
|
| April 21, 2016 |
INTELLECTUAL PROPERTY SECURITY AGREEMENT Exhibit 10.5 EXECUTION VERSION INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property SECURITY AGREEMENT (this “Agreement”), dated as of April 14, 2016, by Amarantus Bioscience Holdings, Inc., a Nevada corporation (the “Grantor”), in favor of as collateral agent (the “Collateral Agent”) for the secured parties referred to below. WHEREAS: A. Reference is made to that certain Security A |
|
| April 21, 2016 |
Certificate of Designation Series H Exhibit 3.2 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 897014201 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporation |
|
| April 21, 2016 |
Exhibit 10.7 EXECUTION VERSION SUBSIDIARY GUARANTEE Subsidiary Guarantee, dated as of April 14, 2016 (this ?Guarantee?), made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the ?Guarantors?), in favor of the purchasers signatory (together with their permitted assigns, the ?Secured Parties?) to that certain Securities Purchase Ag |
|
| April 21, 2016 |
Certificate of Designation Series E EX-3.1 2 f8k041416ex3iamarantus.htm CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATION OF SERIES E CONVERTIBLE PREFERRED STOCK FILED WITH THE NEVADA SECRETARY OF STATE ON APRIL 19, 2016 Exhibit 3.1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 897014201 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or |
|
| April 21, 2016 |
8-K 1 f8k041416amarantusbiosci.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2016 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 |
|
| April 21, 2016 |
COMMON STOCK PURCHASE WARRANT Amarantus Bioscience Holdings, Inc. Exhibit 10.3 EXECUTION VERSION NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO A |
|
| April 21, 2016 |
EX-10.6 9 f8k041416ex10viamarantus.htm FORM OF REGISTRATION RIGHTS AGREEMENT Exhibit 10.6 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 14, 2016, between Amarantus Bioscience Holdings, Inc., a Nevada corporation (the “Company”), and each purchaser signatory hereto (the “Purchasers”). This Agreement is made |
|
| April 21, 2016 |
10% original issue discount SENIOR SECURED CONVERTIBLE PROMISSORY NOTE DUE April 14, 2017 EX-10.2 5 f8k041416ex10iiamarantus.htm FORM OF 10% SENIOR SECURED CONVERTIBLE PROMISSORY NOTES Exhibit 10.2 EXECUTION VERSION NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS A |
|
| April 21, 2016 |
Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of April 14, 2016, by and among AMARANTUS BIOSCIENCE HOLDINGS, INC., a Nevada corporation (and together with all of its current and future, direct and/or indirect, wholly owned and/or partially owned Subsidiaries, collectively, the “Company”) and each purchaser identified on |
|
| March 30, 2016 |
Amarantus Bioscience Holdings NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2015 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report o |
|
| March 14, 2016 |
Amarantus Bioscience Holdings PRELIMINARY REVISED PROXY SOLICITING MATERIALS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 8, 2016 |
Amarantus Bioscience Holdings PRELIMINARY PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 7, 2016 |
Amarantus Bioscience Holdings CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2016 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or o |
|
| March 7, 2016 |
Exhibit 99.1 Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health Companies to hold a Conference Call to discuss the business combination today, March 7, 2015 at 4:30pm ET SCOTTSDALE, Arizona, SAN FRANCISCO and GAITHERSBERG, Maryland, March 7, 2016 /PRNewswire/ - Highlights of Business Combination ● Amarantus Diagnostics and Theranostics Health operations to c |
|
| March 7, 2016 |
8% CONVERTIBLE NOTE DUE February 28, 2017 Exhibit 10.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| March 4, 2016 |
EX-3.1 2 f8k030116ex3iamarantusbios.htm AMENDMENT TO CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E 12% CONVERTIBLE PREFERRED STOCK. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATION OF AMARANTUS BIOSCIENCE HOLDINGS, Inc. Pursuant to Section 78.1955 of the Nevada Revised Statutes SERIES E CONVERTIBLE PREFERRED STOCK On behalf of Amarantus BioScience |
|
| March 4, 2016 |
Amarantus Bioscience Holdings CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2016 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or o |
|
| February 24, 2016 |
Exhibit 3.1 EXECUTION VERSION AMARANTUS BIOSCIENCE HOLDINGS, INC. AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES H 12% CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 78, 1955 OF THE NEVADA REVISED STATUTES The undersigned, Gerald Commissioner, does hereby certify that: 1. He is the President and Chief Executive Officer, of Inc., a Nevada corporati |
|
| February 24, 2016 |
Exhibit 10.3 EXHIBIT D LEAK-OUT AGREEMENT THIS LEAK-OUT AGREEMENT (the ?Agreement?) is made and entered into as of the 19th day of February 2016, and effective as of 22nd February 2016, between Amarantus Bioscience Holdings, Inc., a Nevada corporation (the ?Company?) and the holders (the ?Holders? and each a ?Holder?) of the Company?s issued and outstanding Series E Convertible Preferred Stock and |
|
| February 24, 2016 |
Amarantus Bioscience Holdings CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2016 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation |
|
| February 24, 2016 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of February 18, 2016, between Amarantus BioScience Holdings, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms |
|
| February 24, 2016 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATION OF AMARANTUS BIOSCIENCE HOLDINGS, Inc. Pursuant to Section 78.1955 of the Nevada Revised Statutes SERIES E CONVERTIBLE PREFERRED STOCK On behalf of Amarantus BioScience Holdings, Inc., a Nevada corporation (the ?Corporation?), the undersigned hereby certifies that the following resolution has been duly adopted by the board of direc |
|
| February 24, 2016 |
Amarantus Announces $3M Capital Infusion EX-99.1 8 f8k021916ex99iamarantus.htm AMARANTUS BIOSCIENCE HOLDINGS, INC. PRESS RELEASE, DATED FEBRUARY 19, 2016 Exhibit 99.1 Amarantus Announces $3M Capital Infusion SAN FRANCISCO, CA – February 19, 2016 – Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced the closing of a $3M inves |
|
| February 24, 2016 |
Exhibit 10.4 PLACEMENT AGENCY AGREEMENT February 19, 2016 Chardan Capital Markets, LLC 17 State Street, Suite 1600 New York, NY 10004 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this ?Agreement?), Amarantus BioScinece Holdings, Inc., a Nevada corporation (the ?Company?), hereby agrees to sell up to an aggregate of $8,800,000 of securities (the ?Securities?) of t |
|
| February 24, 2016 |
COMMON STOCK PURCHASE WARRANT AMARANTUS BIOSCIENCE HOLDINGS, INC. Exhibit 10.2 COMMON STOCK PURCHASE WARRANT AMARANTUS BIOSCIENCE HOLDINGS, INC. Warrant Shares: 13,200,000 Initial Exercise Date: February , 2016 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Anson Investments Master Fund LP or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set |
|
| February 24, 2016 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 3,300 Shares of Series H 12% Convertible Preferred Stock Common Stock Purchase Warrant, exercisable for 13,200,000 shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 3,300 shares of Series H 12% Convertible Preferred Stock |
|
| February 23, 2016 |
Amarantus Bioscience Holdings Form PRE 14A PRE 14A 1 def14a0216amarantusbio.htm DEFINITIVE PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| February 18, 2016 |
424B5 1 f424b5021816amarantus.htm PROSPECTUS Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 416.67 Shares of Series H 12% Convertible Preferred Stock Common Stock Purchase Warrant, exercisable for 1,984,143 shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 416.67 shar |
|
| February 9, 2016 |
255.56 Shares of Series E 12% Convertible Preferred Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 255.56 Shares of Series E 12% Convertible Preferred Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 255.56 shares of Series E12% Convertible Preferred Stock, which we refer to as our Series E Preferred Stock, and the common stock issuab |
|
| February 9, 2016 |
Entry into a Material Definitive Agreement 8-K 1 f8k020816amarantusbio.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2016 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other |
|
| January 29, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2016 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation o |
|
| January 29, 2016 |
Exhibit 99.1 Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson?s Disease - Patent issuance will provide intellectual property protection in China for protein therapy, gene therapy and cell therapy applications of MANF - SAN FRANCISCO, CA ? January 29, 2016 ? Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing produc |
|
| January 28, 2016 |
Exhibit 10.4 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this ?Agreement?) is entered into as of January 27, 2016 by and between Amarantus Bioscience Holdings, Inc., a Nevada corporation (the ?Company?), and (the ?Selling Stockholder?). Recitals WHEREAS, the Selling Stockholder beneficially owns an aggregate of 5,882.222 shares of the Company?s Series E Preferred Stock (the ?Series |
|
| January 28, 2016 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of January 27, 2016, by and among Amarantus BioScience Holdings, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the te |
|
| January 28, 2016 |
Amarantus Announces $1M Investment Exhibit 99.1 Amarantus Announces $1M Investment SAN FRANCISCO, CA ? January 27, 2016 ? Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced the closing of a $1M investment from an investor introduced to the Company by International Infusion, LLC. The new investment comes in the form of |
|
| January 28, 2016 |
Exhibit 10.2 LEAK-OUT AGREEMENT THIS LEAK-OUT AGREEMENT (the ?Agreement?) is made and entered into as of the 27th day of January 2016, between Amarantus Bioscience Holdings, Inc., a Nevada corporation (the ?Company?) and the holders (the ?Holders? and each a ?Holder?) of the Company?s issued and outstanding Series E Convertible Preferred Stock and Series H Convertible Preferred Stock (collectively |
|
| January 28, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2016 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation o |
|
| January 28, 2016 |
424B5 1 f424b5012816amarantus.htm PROSPECTUS FILED PURSUANT TO RULE 424(B)(5) Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 1166.666 Shares of Series H 12% Convertible Preferred Stock Common Stock Purchase Warrant, exercisable for 495,833 shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospe |
|
| January 28, 2016 |
Exhibit 10.3 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this ?Agreement?) is entered into as of January 27, 2016 by and between Amarantus Bioscience Holdings, Inc., a Nevada corporation (the ?Company?), and (the ?Selling Stockholder?). Recitals WHEREAS, the Selling Stockholder beneficially owns an aggregate of 2,631.556 shares of the Company?s Series H Preferred Stock (the ?Series |
|
| January 19, 2016 |
Amarantus Enters into Letter of Intent to Merge Diagnostics Business Unit into Avant Diagnostics Exhibit 99.1 Amarantus Enters into Letter of Intent to Merge Diagnostics Business Unit into Avant Diagnostics SAN FRANCISCO, CA and SCOTTSDALE, AZ ? January 19, 2016 ? Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, and Avant Diagnostics (OTCQB: AVDX), a medical diagnostic technology company, tod |
|
| January 19, 2016 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2016 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation o |
|
| January 8, 2016 |
424B5 1 f424b5010816amarantus.htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 110 Shares of Series H 12% Convertible Preferred Stock Common Stock Purchase Warrant, exercisable for 46,750 shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 110 sh |
|
| January 4, 2016 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 220 Shares of Series H 12% Convertible Preferred Stock Common Stock Purchase Warrant, exercisable for 93,500 shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 220 shares of Series H 12% Convertible Preferred Stock, which |
|
| December 29, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to Rules 13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2 (AMENDMENT NO. )* Amarantus Bioscience Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 02300U205 (CUSIP Number) Dec |
|
| December 10, 2015 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation o |
|
| December 9, 2015 |
424B5 1 f424b5120915amarantus.htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 66 Shares of Series H 12% Convertible Preferred Stock Common Stock Purchase Warrant, exercisable for 28,050 shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 66 shar |
|
| December 7, 2015 |
424B5 1 f424b5120715amarantus.htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 242 Shares of Series H 12% Convertible Preferred Stock Common Stock Purchase Warrant, exercisable for 102,850 shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 242 s |
|
| December 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation o |
|
| December 2, 2015 |
Amarantus Bioscience Holdings CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation |
|
| November 27, 2015 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 178.75 Shares of Series H 12% Convertible Preferred Stock Common Stock Purchase Warrant, exercisable for 75,969 shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 178.75 shares of Series H 12% Convertible Preferred Stock, |
|
| November 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: SEPTEMBER 30, 2015 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 000-55016 Amarantus Bioscien |
|
| November 19, 2015 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation |
|
| November 13, 2015 |
424B5 1 v424676424b5.htm 424(B)(5) Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 330 Shares of Series H 12% Convertible Preferred Stock Common Stock Purchase Warrant, exercisable for 140,250 shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 330 shares of Series H 12% |
|
| November 13, 2015 |
Amarantus Bioscience Holdings FORM NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2015 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report |
|
| November 4, 2015 |
Amarantus Bioscience Holdings FORM DEF 14A DEF 14A 1 v423669def14a.htm FORM DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definiti |
|
| November 3, 2015 |
AMARANTUS BIOSCIENCE HOLDINGS, INC. 2015 CONSULTANTS PLAN Exhibit 10.1 AMARANTUS BIOSCIENCE HOLDINGS, INC. 2015 CONSULTANTS PLAN 1. Purpose of the Plan. This 2015 Consultants Plan (the "Plan") is intended as an incentive for consultants and advisors to Amarantus BioScience Holdings, Inc., a Nevada corporation (the "Company"), and any Subsidiary of the Company, within the meaning of Section 424(f) of the United States Internal Revenue Code of 1986, as ame |
|
| November 3, 2015 |
Amarantus Bioscience Holdings FORM S-8 As filed with the Securities and Exchange Commission on November 3, 2015 Registration No. |
|
| October 30, 2015 |
Amarantus Bioscience Holdings ESP Amarantus Bioscience Holdings, Inc. 655 Montgomery Street, Suite 900 San Francisco, CA 94111 October 30, 2015 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Suzanne Hayes and Alla Berenshteyn Re: Amarantus BioScience Holdings, Inc. Registration Statement on Form S-1 File No. 333-207435 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regula |
|
| October 28, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation o |
|
| October 27, 2015 |
424B5 1 v422897424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 330 Shares of Series H 12% Convertible Preferred Stock Common Stock Purchase Warrant, exercisable for 140,250 shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 330 shares of Series H 12% Con |
|
| October 23, 2015 |
Amarantus Bioscience Holdings PRE 14A PRE 14A 1 v422696pre14a.htm PRE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Ad |
|
| October 19, 2015 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 165 Shares of Series H 12% Convertible Preferred Stock Common Stock Purchase Warrant, exercisable for 70,125 shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 165 shares of Series H 12% Convertible Preferred Stock, which |
|
| October 15, 2015 |
S-1 1 v421634s1.htm S-1 As filed with the Securities and Exchange Commission on October 15, 2015 Registration No. 333 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Amarantus BioScience Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 2834 26-0690857 (State or other jurisdiction |
|
| October 8, 2015 |
Exhibit 99.1 Amarantus Reports Preliminary 13-Year Longitudinal Follow-Up Human Patient Data for Engineered Skin Substitute Treatment of Congenital Giant Hairy Nevus - Single ESS treatment provided successful skin replacement on infant patient, supporting natural skin growth that required no additional grafts or reconstructive surgery - Data provides translational support for multiple pediatric sk |
|
| October 8, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v4218398k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jur |
|
| October 8, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or |
|
| October 8, 2015 |
Exhibit 99.1 Tissue Products for Emergency Preparedness Symposium – May 2015 OASH Office of the Assistant Secretary for Health Experience with an Autologous Bilayered Engineered Skin Replacement Richard J. Kagan, MD, FACS Chief of Staff, Emeritus Shriners Hospitals for Children, Cincinnati Consultant, Lonza, Inc. 1 Operative Strategy for the Closure of Full-thickness Burns Small < 20% TBSA Medium |
|
| October 1, 2015 |
12% SENIOR SECURED CONVERTIBLE PROMISSORY NOTE DUE September 29, 2016 Exhibit 10.4 EXECUTION VERSION NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO |
|
| October 1, 2015 |
AMARANTUS BIOSCIENCE HOLDINGS, INC. Letter Agreement September 30, 2015 Exhibit 10.9 AMARANTUS BIOSCIENCE HOLDINGS, INC. Letter Agreement dated September 30, 2015 This letter agreement dated September 30, 2015 (this “Letter Agreement”) amends that (i) Securities Purchase Agreement dated September 30, 2015 (the “SPA”) by and between Amarantus Bioscience Holdings, Inc. (the “Company”) and Delafield Investments Limited (“Delafield”) and (ii) Exchange Agreement dated Sept |
|
| October 1, 2015 |
PATENT AND TRADEMARK SECURITY AGREEMENT Exhibit 10.6 PATENT AND TRADEMARK SECURITY AGREEMENT This PATENT AND TRADEMARK SECURITY AGREEMENT, dated as of September 30, 2015 (this ?Agreement?), is among Amarantus Bioscience Holdings, Inc. (the ?Company?), and Subsidiaries of the Company, which Subsidiaries are set forth on Schedule 1 hereto (such Subsidiaries, together with the Company, collectively the ?Debtors?) and the holders of the Com |
|
| October 1, 2015 |
COMMON STOCK PURCHASE WARRANT Amarantus Bioscience Holdings, Inc. Exhibit 10.2 EXECUTION COPY OF RD WARRANT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PU |
|
| October 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation |
|
| October 1, 2015 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 3,055.556 Shares of Series H 12% Convertible Preferred Stock Common Stock Purchase Warrant, exercisable for 1,298,612 shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 3,055.556 shares of Series H 12% Convertible Preferre |
|
| October 1, 2015 |
Exhibit 10.8 EXECUTION COPY REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of September 30, 2015, between Amarantus Bioscience Holdings, Inc., a Nevada corporation (the ?Company?), and each of the persons signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to (i) |
|
| October 1, 2015 |
Exhibit 99.1 Amarantus Closes $5.5 Million Capital Infusion through the Issuance of a Combination of Preferred Stock and Secured Debt Convertible Company Simultaneously Repurchases All Outstanding Series G Convertible Preferred Stock SAN FRANCISCO, CA, and GENEVA, SWITZERLAND ? October 1, 2015 ? Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapeutic and d |
|
| October 1, 2015 |
Exhibit 10.5 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of September 30, 2015 (this “Agreement”), is among Amarantus Bioscience Holdings, Inc. (the “Company”), all of the Subsidiaries of the Company, which Subsidiaries are set forth on Schedule 1 hereto the Subsidiaries, and together with the Company, collectively the “Debtors”) and the holders of the Company’s 12% Senior Secured Convert |
|
| October 1, 2015 |
Exhibit 10.3 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT dated as of September 30, 2015 by and among DELAFIELD INVESTMENTS LIMITED (LENDER) and AMARANTUS BIOSCIENCE HOLDINGS, INC. (BORROWER) SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of September 30, 2015, by and among AMARANTUS BIOSCIENCE HOLDINGS, INC., a Nevada corporation (and together wit |
|
| October 1, 2015 |
Exhibit 10.10 REPURCHASE AGREEMENT This Agreement (the "Agreement") is made on the 25th day of September 2015 (?Effective Date?) by and between Amarantus Bioscience Holdings, Inc., a Nevada corporation with its principal place of business at 655 Montgomery Street, Suite 900, San Francisco, California 94111 (the "Company") and Discover Growth Fund, a Cayman Islands exempted mutual fund with its pri |
|
| October 1, 2015 |
Exhibit 10.7 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the ?Agreement?) is dated this 30th day of September, 2015, by and among AMARANTUS BIOSCIENCE HOLDINGS, INC., a Nevada corporation (the ?Company?), all of the subsidiaries of the Company that are party to the Agreement (collectively, ?Subsidiaries?), and DOMINION CAPITAL LLC (the ?Holder?). WHEREAS, the Holder beneficially owns and holds cer |
|
| October 1, 2015 |
Exhibit 3.1 EXECUTION VERSION AMARANTUS BIOSCIENCE HOLDINGS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES H 12% CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 78, 1955 OF THE NEVADA REVISED STATUTES The undersigned, Gerald Commissioner, does hereby certify that: 1. He is the President and Chief Executive Officer, of Inc., a Nevada corporation (the “Corporation” |
|
| October 1, 2015 |
Exhibit 10.1 Execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 30, 2015 by and among Amarantus BioScience Holdings, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, s |
|
| September 14, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 v4202628k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other juris |
|
| September 14, 2015 |
Exhibit 99.1 Amarantus Receives Orphan Drug Designation from the U.S. Food and Drug Administration for MANF for the Treatment of Retinal Artery Occlusion SAN FRANCISCO, CA, and GENEVA, SWITZERLAND ? September 14, 2015 ? Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced t |
|
| September 3, 2015 |
Amarantus Bioscience Holdings 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation |
|
| September 3, 2015 |
Amarantus Announces Results of Annual Meeting Exhibit 99.1 Amarantus Announces Results of Annual Meeting SAN FRANCISCO, CA, and GENEVA, SWITZERLAND ? September 3, 2015 ? Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced that at its 2015 Annual Meeting of Stockholders held yesterday in New York, New York, the stockho |
|
| August 26, 2015 |
Amarantus Bioscience Holdings DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials o Soliciting Material Pursuant to §240. |
|
| August 26, 2015 |
Amarantus Bioscience Holdings DEFA14A DEFA14A 1 v419182defa14a.htm DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive A |
|
| August 20, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or |
|
| August 20, 2015 |
EX-99.1 2 v418723ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Amarantus Announces Issuance of United States Patent Covering Proprietary Compositions of Matter and Methods of Use for Product Candidate MANF SAN FRANCISCO, CA, and GENEVA, SWITZERLAND – August 20, 2015 – Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orpha |
|
| August 17, 2015 |
Exhibit 99.1 Amarantus Reports Second Quarter 2015 Financial Results and Business Overview SAN FRANCISCO and GENEVA, Aug. 17, 2015 (GLOBE NEWSWIRE) - Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced financial results for the second quarter ended June 30, 2015. The Company also |
|
| August 17, 2015 |
Amarantus Bioscience Holdings 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or |
|
| August 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 v41722710q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: JUNE 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 0 |
|
| August 7, 2015 |
Amarantus Bioscience Holdings FORM DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| August 6, 2015 |
8-K 1 v4172958k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdicti |
|
| August 4, 2015 |
Amarantus Bioscience Holdings DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials o Soliciting Material Pursuant to ?240. |
|
| August 4, 2015 |
Amarantus Bioscience Holdings DEFA14A DEFA14A 1 v417033defa14a.htm DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive A |
|
| August 3, 2015 |
Amarantus Announces Adjournment of Annual Meeting Exhibit 99.2 Amarantus Announces Adjournment of Annual Meeting SAN FRANCISCO, CA, and GENEVA, SWITZERLAND ? August 3, 2015 ? Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced that its 2015 Annual Meeting of Stockholders scheduled for, and convened on August 3, 2015, was |
|
| August 3, 2015 |
Ticker: OTCQX:AMBS www.amarantus.com Annual Meeting of Shareholders August 3, 2015 Exhibit 99.1 Ticker: OTCQX:AMBS www.amarantus.com Annual Meeting of Shareholders August 3, 2015 Forward - Looking Statements This presentation contains ? forward - looking statements ? within the meaning of the ? safe - harbor ? provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the a |
|
| August 3, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K 1 v4169548k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdict |
|
| July 22, 2015 |
Exhibit 99.1 Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro? Blood Diagnostic for Alzheimer?s Disease and Confirms LymPro?s Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer?s Association International Conference? ? LymPro discriminates Alzheimer?s disease (AD) from healthy controls with comparable accuracy to clinic |
|
| July 22, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 v4159818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdicti |
|
| July 21, 2015 |
Amarantus Bioscience Holdings DEF 14A DEF 14A 1 v415847def14a.htm DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement o Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Ad |
|
| July 20, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 v4158378k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdicti |
|
| July 20, 2015 |
Exhibit 99.1 Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia - Top-line Phase 2b results expected in 1H 2016 - SAN FRANCISCO, CA, and GENEVA, SWITZERLAND – July 20, 2015 – Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan |
|
| July 16, 2015 |
Up to 520,345 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Under the Securities Act of 1933, as amended Registration No. |
|
| July 15, 2015 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 9, 2015, between Amarantus Bioscience Holdings, Inc., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and c |
|
| July 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or or |
|
| July 15, 2015 |
EX-99.2 11 v415358ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Amarantus Completes Acquisition of ESS from Lonza for the Treatment of Severe Burns - Amarantus now has full ownership of Cutanogen Corporation, which has exclusive worldwide license to Orphan Drug Product Candidate Engineered Skin Substitute (ESS) - SAN FRANCISCO, CA, and GENEVA, SWITZERLAND – July 15, 2015 - Amarantus BioScience Holdings, In |
|
| July 15, 2015 |
AMENDED AND RESTATED STOCK PURCHASE AGREEMENT Exhibit 10.1 AMENDED AND RESTATED STOCK PURCHASE AGREEMENT This Amended and Restated Stock Purchase Agreement (?Agreement?) is made and entered into on July 9, 2015 (?Effective Date?), by and between Amarantus BioScience Holdings, Inc., a Nevada corporation (?Company?), and (?Investor?). Recitals A. The parties desire that, upon the terms and subject to the conditions herein, Investor will purchas |
|
| July 15, 2015 |
Exhibit 99.1 Amarantus to Commence Trading on the OTCQX Marketplace under Existing Ticker Symbol AMBS - Company progressing toward a national stock exchange listing - SAN FRANCISCO, CA and GENEVA, SWITZERLAND, July 13, 2015 - Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for diseases in the areas of neurology, p |
|
| July 15, 2015 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July , 2015, between Amarantus Bioscience Holdings, Inc. (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and conditions set forth in |
|
| July 15, 2015 |
12% PROMISSORY NOTE DUE July 9, 2016 EX-10.4 8 v415358ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER |
|
| July 15, 2015 |
Exhibit 10.5 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of July , 2015 (this ?Agreement?), is among Amarantus Bioscience Holdings, Inc. (the ?Company?), all of the Subsidiaries of the Company (such subsidiaries, the ?Guarantors? and together with the Company, the ?Debtors?) and the holders of the Company?s 12% Promissory Notes due twelve (12) months from the date hereof, in the original |
|
| July 15, 2015 |
Certificate of Designation Series G Exhibit 3.1(b) AMARANTUS BIOSCIENCE HOLDINGS, INC. AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES G PREFERRED STOCK The undersigned, Gerald E. Commissiong and Robert Farrell, hereby certify that: 1. The undersigned are the Chief Executive Officer and Chief Financial Officer, respectively, of Amarantus BioScience Holdings, Inc., a Nevada corporatio |
|
| July 15, 2015 |
EX-3.1(A) 2 v415358ex3-1a.htm EXHIBIT 3.1(A) Exhibit 3.1(a) AMARANTUS BIOSCIENCE HOLDINGS, INC. SECOND AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E 12% CONVERTIBLE PREFERRED STOCK (PURSUANT TO NRS 78.1955) The undersigned, Gerald E. Commissiong and Marc E. Faerber, do hereby certify that: 1. They are the Chief Executive Officer and Secretary, r |
|
| July 10, 2015 |
Amarantus Bioscience Holdings PRE 14A PRE 14A 1 v414356pre14a.htm PRE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Ad |
|
| July 10, 2015 |
535 Shares of Series G Preferred Stock and up to 3,297,222 Shares of Common Stock 424B5 1 v415285424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Amendment No. 1 dated July 10, 2015 to Prospectus Supplement dated July 9, 2015 (To Prospectus Dated May 22, 2015) 535 Shares of Series G Preferred Stock and up to 3,297,222 Shares of Common Stock This amendment no. 1 to prospectus supplement amends the prospectus supplement dated July 9, 2015. We are offer |
|
| July 9, 2015 |
435 Shares of Series G Preferred Stock and up to 3,241,667 Shares of Common Stock 424B5 1 v414680424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-203845 Prospectus Supplement (To Prospectus Dated May 22, 2015) 435 Shares of Series G Preferred Stock and up to 3,241,667 Shares of Common Stock We are offering directly to an institutional investor for total gross proceeds of $2,000,000 435 shares of Series G Preferred Stock and up to 241,667 shares of common st |
|
| July 8, 2015 |
8-K 1 v4147718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdictio |
|
| July 8, 2015 |
12% PROMISSORY NOTE DUE APRIL 2, 2016 Exhibit 10.1 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVA |
|
| June 23, 2015 |
As filed with the Securities and Exchange Commission on June 23, 2015 Registration No. |
|
| June 15, 2015 |
Exhibit 99.1 Amarantus Announces Presentation of Eltoprazine Phase 1/2a Clinical Data at the 19th International Congress of Parkinson?s Disease and Movement Disorders - Poster Presentation on June 15, 2015 from 12:30-2:00 p.m. PDT - SAN FRANCISCO, CA, and GENEVA, SWITZERLAND ? June 15, 2015 - Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing therapeut |
|
| June 15, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or o |
|
| June 9, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or or |
|
| June 9, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or or |
|
| June 9, 2015 |
Amarantus Completes Capital Restructuring in Preparation for National Exchange Listing EX-99.1 2 v412813ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Amarantus Completes Capital Restructuring in Preparation for National Exchange Listing SAN FRANCISCO and GENEVA, June 9, 2015 (GLOBE NEWSWIRE) - Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced it has c |
|
| June 9, 2015 |
Exhibit 99.1 Amarantus Diagnostics Announces Acceptance of Two Late-Breaking Abstracts on LymPro Test® Data at the 2015 Alzheimer’s Association International Conference® -Amarantus Diagnostics is a Silver Sponsor of AAIC- SAN FRANCISCO, CA, and GENEVA, SWITZERLAND – June 9, 2015 - Amarantus Diagnostics, a neurology-focused diagnostics company developing diagnostic tests for Multiple Sclerosis and |
|
| June 5, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or or |
|
| June 5, 2015 |
Exhibit 99.1 Amarantus Opens First Clinical Trial Site and Commences Patient Enrollment for Lead Product Candidate Eltoprazine's Phase 2b Study in Parkinson's Disease Levodopa-Induced Dyskinesia - Study Commenced at the Parkinson's Disease and Movement Disorders Center of Boca Raton, a Nationally Recognized Leading Clinical Research Institution SAN FRANCISCO and GENEVA, June 5, 2015 (GLOBE NEWSWIR |
|
| May 28, 2015 |
Exhibit 99.1 1 Developing clinical - stage products in neurology, psychiatry and orphan indications BUSINESS UPDATE CONFERENCE CALL May 27, 2015 OTCQB: AMBS This presentation contains ? forward - looking statements ? within the meaning of the ? safe - harbor ? provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and othe |
|
| May 28, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or or |
|
| May 26, 2015 |
Exhibit 99.1 Amarantus to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015 - Presentation and Webcast on May 28, 2015, at 9:00 a.m. EDT - SAN FRANCISCO and GENEVA, May 26, 2015 (GLOBE NEWSWIRE) - Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan |
|
| May 26, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 v4116108k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdictio |
|
| May 22, 2015 |
Exhibit 99.1 Amarantus Effects Capital Restructuring in Anticipation of National Exchange Listing -Company Announces 1-for-150 Reverse Stock Split- SAN FRANCISCO, CA, and GENEVA, SWITZERLAND ? May 22, 2015 - Amarantus BioSciences Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announc |
|
| May 22, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or or |
|
| May 21, 2015 |
Exhibit 3.1 |
|
| May 21, 2015 |
8-K 1 v4114698k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdictio |
|
| May 21, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 v4113818k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisd |
|
| May 21, 2015 |
Exhibit 99.1 Amarantus Enters into CRO Agreement with Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia - Company Completes Investigator Meetings in U.S. and E.U. in Preparation for Study Launch - - Enrollment and Dosing for 60-Patient PD-LID Study on Track to Commence 2Q 2015 - SAN FRANCISCO, CA, and GENEVA, SWITZERL |
|
| May 20, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or or |
|
| May 20, 2015 |
EX-99.1 2 v411155ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Amarantus Reports First Quarter 2015 Financial Results and Business Overview - Eltoprazine Phase 2b clinical program on track to commence in 2Q 2015 - - Management to host conference call and webcast on Wednesday, May 27, 2015 at 5:00 p.m. EDT - SAN FRANCISCO, CA, and GENEVA, SWITZERLAND – May 20, 2015 - Amarantus BioScience Holdings, Inc. (OTC |
|
| May 20, 2015 |
EX-99.2 3 v411155ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Amarantus to Present at Two Upcoming Investor Conferences -Marcum Microcap Conference Presentation on May 28, 2015, at 2:30 p.m. EDT / 11:30 a.m. PDT- -LD Micro Invitational Presentation and Webcast on June 2, 2015, at 1:30 p.m. EDT / 10:30 a.m. PDT- SAN FRANCISCO, CA, and GENEVA, SWITZERLAND – May 19, 2015 - Amarantus BioScience Holdings, Inc. |
|
| May 19, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: MARCH 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 000-55016 Amarantus Bioscience H |
|
| May 15, 2015 |
Amarantus Bioscience Holdings NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: March 31, 2015 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on F |
|
| May 15, 2015 |
Exhibit 99.1 Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson?s Disease -Collaboration using Renishaw plc?s convection-enhanced delivery device demonstrated MANF can be precisely delivered to Parkinson?s-associated brain areas- -Delivery and distribution data solidifies rationale for preclinical development of MANF as a pote |
|
| May 15, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 v4108948k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdictio |
|
| May 14, 2015 |
Exhibit 99.1 Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies - Catalent to Utilize Proprietary GPEx(R) Platform for Production of High Performance MANF Expressing Cell Line - - cGMP Production of MANF to Enable Program Advancement Into Human Clinical Studies in Retinitis Pigmentosa, Retinal Artery Occlusion, Glaucoma and |
|
| May 14, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or or |
|
| May 13, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or or |
|
| May 13, 2015 |
Exhibit 99.1 Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease Patent Issuance Will Provide IP Protection for Lead Product Candidate Eltoprazine for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID) SAN FRANCISCO and GENEVA, Switzerland, May 13, 2015 (GLOBE N |
|
| May 11, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or or |
|
| May 11, 2015 |
Exhibit 99.1 Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise(R) Diagnostic for Multiple Sclerosis -MSPrecise blood diagnostic shows statistically significant sensitivity and specificity for classifying presentation of multiple sclerosis- -Data supports further research into blood-based approach - SAN FRANCISCO, May 11, 2015 (GLOBE NEWSWIRE) - Amarantus BioScience Holdings, |
|
| May 8, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 v4100818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction |
|
| May 8, 2015 |
EX-99.1 2 v410081ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Amarantus Announces the Presentation of Data Showing MANF’s Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Study conducted by leading researchers at University of Miami - - Data demonstrate MANF preserves photoreceptor cells and light-sensing function - SAN FRANCISCO, CA, and |
|
| May 5, 2015 |
Amarantus Bioscience Holdings FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or org |
|
| May 5, 2015 |
Exhibit 99.1 Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF - Patent issuance will provide additional IP protection for MANF protein therapy and cell therapy - SAN FRANCISCO, CA, and GENEVA, SWITZERLAND ? May 5, 2015 - Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on dev |
|
| May 4, 2015 |
Amarantus Bioscience Holdings FORM S-3 As filed with the Securities and Exchange Commission on May 4, 2015 Registration No. |
|
| May 4, 2015 |
Exhibit 4.1 |
|
| May 4, 2015 |
Amarantus Bioscience Holdings FORM S-3 S-3 1 v409120s3.htm FORM S-3 As filed with the Securities and Exchange Commission on May 4, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Amarantus Bioscience Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 26-0690857 (State or other jurisdiction of incor |
|
| May 4, 2015 |
Exhibit 4.1 |
|
| April 29, 2015 |
Exhibit 99.1 Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa SAN FRANCISCO, CA, and GENEVA, SWITZERLAND ? April 29, 2015 - Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that the European Commi |
|
| April 29, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or |
|
| April 28, 2015 |
EX-3.1 2 v408542ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 AMARANTUS BIOSCIENCE HOLDINGS, INC. CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES G PREFERRED STOCK The undersigned, Gerald E. Commissiong and Robert Farrell, hereby certify that: 1. The undersigned are the Chief Executive Officer and Chief Financial Officer, respectively, of Amarantus BioScience Holdings, Inc., a Nev |
|
| April 28, 2015 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (?Agreement?) is made and entered into on April 23, 2015 (?Effective Date?), by and between Amarantus BioScience Holdings, Inc., a Nevada corporation (?Company?), and Discover Growth Fund, a Cayman Islands exempted mutual fund (?Investor?). Recitals A. The parties desire that, upon the terms and subject to the conditions herein, I |
|
| April 28, 2015 |
Amarantus Bioscience Holdings FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or |
|
| April 28, 2015 |
EX-99.1 4 v408542ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Amarantus Closes $5 Million Preferred Stock Financing -Company issues Series "G" preferred stock convertible into common shares at a fixed price of $0.06 per share- SAN FRANCISCO, CA, and GENEVA, SWITZERLAND – April 27, 2015 – Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing diagnostics in neurolo |
|
| April 9, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 333-148922 26-0690857 (State or other jurisdiction of incorporation or |
|
| April 9, 2015 |
Exhibit 99.1 1 Developing clinical - stage products in neurology, psychiatry and orphan indications BUSINESS UPDATE CONFERENCE CALL April 9, 2015 OTCQB: AMBS This presentation contains “ forward - looking statements ” within the meaning of the “ safe - harbor ” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and oth |
|
| April 7, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or o |
|
| April 7, 2015 |
Exhibit 99.1 Amarantus Reports 2014 Financial Results and Business Overview -Management to Host Conference Call and Webcast on April 9, 2015 at 11:00 a.m. EDT- SAN FRANCISCO, CA, and GENEVA, SWITZERLAND ? April 7, 2015 - Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products in the areas of neurology, psyc |
|
| April 6, 2015 |
AMENDMENT TO ASSET PURCHASE AGREEMENT Exhibit 10.52 AMENDMENT TO ASSET PURCHASE AGREEMENT This AMENDMENT TO ASSET PURCHASE AGREEMENT, dated January 30, 2015, (the “Amended Agreement”), is intended to amend that certain Asset Purchase Agreement dated November 7, 2014 (the “Original Agreement”), by and among Amarantus Bioscience Holdings, Inc., a Nevada corporation (“Amarantus”), Regenicin, Inc., a Nevada corporation (“Regenicin”), Clar |
|
| April 6, 2015 |
AMENDMENT NO. 2 TO OPTION AGREEMENT EXHIBIT 10.53 AMENDMENT NO. 2 TO OPTION AGREEMENT This AMENDMENT NO. 2 TO OPTION AGREEMENT (the ?Second Amendment?), dated February 6, 2015,(the ?Second Amendment Effective Date?), amends that certain Option Agreement dated October 27, 2014 (the ?Original Agreement?) as amended by the First Amendment to the Option Agreement dated January 5, 2015 (the ?First Amendment? and together with the Origina |
|
| April 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) 10-K 1 v40126110k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to 000-55016 (Commission file number) Amarantus Biosc |
|
| April 6, 2015 |
Exhibit 10.54 AMARANTUS BIOSCIENCE HOLDINGS, INC. AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E 12% CONVERTIBLE PREFERRED STOCK (PURSUANT TO NRS 78.1955) The undersigned, Gerald E. Commissiong and Marc E. Faerber, do hereby certify that: 1. They are the Chief Executive Officer and Secretary, respectively, of Amarantus BioScience Holdings, Inc., |
|
| April 6, 2015 |
Exhibit 21.1 Subsidiaries Amarantus Therapeutics, Inc., a Nevada corporation Amarantus Therapeutics, Inc., a Delaware corporation Amarantus MA, Inc., a Massachusetts corporation Amarantus Diagnostics Inc., a Delaware corporation |
|
| April 2, 2015 |
Amarantus Bioscience Holdings 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or |
|
| March 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-55016 26-0690857 (State or other jurisdiction of incorporation or |
|
| March 31, 2015 |
AMENDMENT NO. 3 TO OPTION AGREEMENT Exhibit 10.1 AMENDMENT NO. 3 TO OPTION AGREEMENT This AMENDMENT NO. 3 TO OPTION AGREEMENT (the ?Third Amendment?), dated March 27, 2015,(the ?Third Amendment Effective Date?), amends that certain Option Agreement dated October 27, 2014 (the ?Original Agreement?) as amended by the First Amendment to the Option Agreement dated January 5, 2015 (the ?First Amendment?) and by the Second Amendment to th |
|
| March 31, 2015 |
Amarantus Bioscience Holdings NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report o |
|
| March 25, 2015 |
Exhibit 99.3 AMARANTUS BIOSCIENCE HOLDINGS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AMARANTUS BIOSCIENCE HOLDINGS, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 2014 (in thousands) Pro Forma Adjustments Pro Forma Amarantus Diogenix (note x) Consolidated Assets Current Assets Cash and cash equivalents $ 680 $ 1,457 $ (1,438 ) a, c, d |
|
| March 25, 2015 |
Diogenix, Inc. Financial Statements Years Ended December 31, 2013 and 2012 Exhibit 99.1 FINANCIAL STATEMENTS Diogenix, Inc. Years Ended December 31, 2013 and 2012 With Report of Independent Auditors Diogenix, Inc. Financial Statements Years Ended December 31, 2013 and 2012 Contents Independent Auditors? Report 1 Balance Sheets 2 Statements of Operations 3 Statements of Shareholders? Deficit 4 Statements of Cash Flows 5 Notes to Financial Statements 6 INDEPENDENT AUDITORS |
|
| March 25, 2015 |
Exhibit 99.2 UNAUDITED COMPARATIVE FINANCIAL STATEMENTS Diogenix, Inc. Nine Months Ended September 30, 2014 and 2013 Diogenix, Inc. Unaudited Comparative Financial Statements Nine Months Ended September 30, 2014 and 2013 Contents Comparative Balance Sheets September 30, 2014 and December 31, 2013 1 Comparative Statements of Operations 2 Comparative Statements of Cash Flows 3 Notes to Financial Sta |
|
| March 25, 2015 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2015 AMARANTUS BIOSCIENCE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 333-148922 26-0690857 (State or other jurisdiction of incorporation |
